Kymera Therapeutics, Inc.

NASDAQ:KYMR

Biotechnology

Healthcare
$121.13 +1.67%

+$1.50 today

Market cap
$10.34B
Beta
2.03
P/E (TTM)
-28.3
EPS (TTM)
-$3.23
52W Low $36.65High $103.00

Volume 0.68M

Average 0.58M

KYMR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Kymera Therapeutics, Inc.NASDAQ: KYMR

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue remains negative

Q2 FY2026 cost of revenue was $0, compared with $2.08M a year earlier. Trailing-twelve-month cost of revenue was -$2.08M.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$521K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
-$2.08M-200.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How KYMR compares with its peers on the latest reported figures

  • KYMR's LTM Jun 2026 cost of revenue of -$2.08M is the lowest of the 5 companies compared; the peer median is $2.16M.
  • Its year-over-year change of -200.0% is the lowest of 5, against a peer median of -29.2%.
  • Cost of revenue amounts to 2.0% of revenue for KYMR, versus a peer median of 4.9%.
KYMR Competitors Peer median
Cost of Revenue for KYMR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$94.76M -56.9%-53.2%13.5%
ARVNArvinas, Inc.LTM Mar 2026$2.3M +35.3%—2.6%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$2.03M -1.5%—4.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$1.8M -69.3%—5.2%
KYMRKymera Therapeutics, Inc.LTM Jun 2026-$2.08M -200.0%—2.0%
Peer median (excluding KYMR) $2.16M-29.2%-53.2%4.9%

Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue72.83M46.83M78.59M47.07M39.2M
Cost of Revenue00000
Gross Profit72.83M46.83M78.59M47.07M39.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development137.02M164.25M189.08M240.25M316.6M
Selling, General & Admin36.35M43.83M55.04M63.53M68.2M
Operating Expenses173.36M208.08M244.12M308.71M388.6M
Depreciation & Amortization2.4M2.98M3.57M7.37M8.31M
EBITDA(97.65M)(151.66M)(143.2M)(216.24M)(303.06M)
EBITDA Margin-134.1%-323.9%-182.2%-459.4%-773.1%
Operating Income(100.53M)(161.26M)(165.53M)(261.64M)(349.4M)
Operating Margin-138.0%-344.4%-210.6%-555.8%-891.3%
Interest Income488K6.62M18.76M38.03M38.03M
Interest Expense175K176K196K249K249K
Other Income / Expenses313K6.45M18.57M37.78M37.78M
Income Before Tax(100.22M)(154.81M)(146.96M)(223.86M)(311.62M)
Pre-Tax Margin-137.6%-330.6%-187.0%-475.6%-795.0%
Income Tax Expense00000
Net Income(100.22M)(154.81M)(146.96M)(223.86M)(311.4M)
Net Margin-137.6%-330.6%-187.0%-475.6%-794.4%
EPS (Basic)(2.09)(2.87)(2.52)(2.98)(3.69)
EPS (Diluted)(2.09)(2.87)(2.52)(2.98)(3.69)
Weighted Avg Shares47.99M53.93M58.37M75.04M84.39M
Weighted Avg Shares (Diluted)47.99M53.93M58.37M75.04M84.39M

Kymera Therapeutics, Inc.

NASDAQ:KYMR

Intrinsic Alpha fair value

Locked

Current Price

$121.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.